Hjem › Ikke-småcellet lungekreft
Kliniske studier for Ikke-småcellet lungekreft rekrutterer i USA
429 studier for Ikke-småcellet lungekreft rekrutterer deltakere på steder over hele USA.
Byer med flest studier
- Houston, TX145 studier
- New York City, NY120 studier
- Arlington, VA104 studier
- Nashville, TN97 studier
- Boston, MA90 studier
- Los Angeles, CA87 studier
- St. Louis, MO73 studier
- Chicago, IL61 studier
- Baltimore, MD60 studier
- San Antonio, TX59 studier
- Columbus, OH56 studier
- Washington, DC55 studier
- Seattle, WA53 studier
- Dallas, TX52 studier
- Tampa, FL51 studier
- Philadelphia, PA51 studier
- Queens, NY49 studier
- Pittsburgh, PA48 studier
- San Diego, CA48 studier
- Atlanta, GA47 studier
- Edison, NJ47 studier
- Portland, OR46 studier
- Santa Monica, CA45 studier
- Grand Rapids, MI44 studier
- Detroit, MI44 studier
- Orlando, FL44 studier
- Cleveland, OH43 studier
- New Haven, CT41 studier
- Durham, NC39 studier
- Jacksonville, FL39 studier
- Rochester, MN37 studier
- Baldwin Park, CA36 studier
- San Francisco, CA36 studier
- Cincinnati, OH35 studier
- Indianapolis, IN32 studier
- Kansas City, MO31 studier
- Miami, FL31 studier
- Salt Lake City, UT31 studier
- Aurora, CO30 studier
- Austin, TX30 studier
Etter delstat
- Alabama36 studier
- Alaska11 studier
- Arizona66 studier
- Arkansas34 studier
- California207 studier
- Colorado73 studier
- Connecticut55 studier
- Delaware21 studier
- District of Columbia38 studier
- Florida155 studier
- Georgia73 studier
- Hawaii10 studier
- Idaho18 studier
- Illinois94 studier
- Indiana49 studier
- Iowa29 studier
- Kansas34 studier
- Kentucky46 studier
- Louisiana26 studier
- Maine16 studier
- Maryland76 studier
- Massachusetts102 studier
- Michigan101 studier
- Minnesota69 studier
- Mississippi20 studier
- Missouri86 studier
- Montana18 studier
- Nebraska40 studier
- Nevada25 studier
- New Hampshire17 studier
- New Jersey88 studier
- New Mexico22 studier
- New York169 studier
- North Carolina79 studier
- North Dakota15 studier
- Ohio121 studier
- Oklahoma31 studier
- Oregon60 studier
- Pennsylvania103 studier
- Rhode Island13 studier
- South Carolina30 studier
- South Dakota20 studier
- Tennessee118 studier
- Texas204 studier
- Utah56 studier
- Vermont7 studier
- Virginia137 studier
- Washington84 studier
- West Virginia14 studier
- Wisconsin45 studier
Nylig oppdaterte studier
Offisiell studietekst (engelsk)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT04267848A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06623422Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT02146170Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06472245A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07293247The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT04585750A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06465069A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07680764Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07751042A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07365319A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06270706Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06265285Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT05176483Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06918132A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06780085A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07513376A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06172478177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07189871A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07090499Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07388524A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07155187Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06625775A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06907615A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07554339A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07190248Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.